The Institute for Transpersonal and Cannabinergic Integrative Medicine
Here at the ITCIM, we are interested in exploring the applications of two overlapping groups of naturally produced medicinal agents. First, we study medicinals that have transpersonal effects, which is to say that they help to lead subjects beyond ordinary egoic states of consciousness into broader and potentially therapeutic alternate states of consciousness. Secondly, we study medicines, mainly derived from the botanical Cannabis sativa, that exhibit cannabinergic effects in subjects, which means that part of their activity involves augmenting or modifying endogenous cannabinoid signaling and related physiological processes which can have a direct or indirect impact on mood state, memory, inflammation, pain experience, muscle tone, appetite, energy expenditure, bone growth, neuroprotection and neurogenesis, tumor surveillance and apoptosis , immune function, HPA stress axis modulation, and seizure threshold, amongst other systemic functions. We are interested in being a self-sufficient research, treatment, and training institute that sustainably produces these medicinal agents through controlled breeding, cultivation, and development using donated germplasm accessions from around the world and tests them on subjects in inpatient and outpatient clinical and empiric treatment trials, thereby generating a robust body of clinical and agronomic data to further substantiate and uncover their already-known and future-promising therapeutic utilities for the benefit of humankind.
In order to accomplish this in the current legal environment, we require federal government licenses to possess, produce, and prescribe many of these medicinals, an academic institutional home with production and testing spaces, significant funding, and a highly qualified team of researchers. All of this can be done.
Health conditions which we would be interested in studying for treatment, both palliative and curative, include:
Existential Death Anxiety in the Terminally Ill
Chronic Pain Syndromes
Spinal Cord Injuries
to name a few…
Scotton BW, Chinen AB, and Battista JR. (Eds.) 1996. Textbook of Transpersonal Psychiatry and Psychology. New York: Basic Books
Pacher P, Batkai S, Kunos G. 2006. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 2006 Sep;58(3):389-462. Available at: http://pharmrev.aspetjournals.org/cgi/reprint/58/3/389.pdf
Cracker LE and Gardner ZE. 2006. Medicinal Plants and Tomorrow’s Pharmacy: An American Perspective, in R.J. Bogers, L.E. Craker and D. Lange (eds.), Medicinal and Aromatic Plants, Chapter 2, 29-41
Aggarwal SK. Cannabinergic Pain Medicine: A Concise Clinical Primer and Survey of Randomized-controlled Trial Results. Clinical Journal of Pain. 2012 Feb 23. Epub ahead of print. PMID: 22367503